MediciNova Announces Poster Presentation of COMBAT-ALS Clinical Trial at the 36th International Symposium on ALS/MND
MWN-AI** Summary
MediciNova, Inc. has announced that an abstract related to its Phase 2b/3 COMBAT-ALS clinical trial focusing on MN-166 (ibudilast) for treating Amyotrophic Lateral Sclerosis (ALS) will be presented at the upcoming 36th International Symposium on ALS/MND, scheduled from December 5-7, 2025, in San Diego, California. The poster presentation, designated as Paper Number 228, will cover updates on trial progress and patient baseline characteristics, contributing to the broader discourse on clinical trials and their design.
MN-166 (ibudilast) is a small molecule that acts as a phosphodiesterase type-4 (PDE4) inhibitor, targeting inflammatory cytokines such as macrophage migration inhibitory factor (MIF). This compound is currently in late-stage clinical trials for ALS, and it is also being investigated for multiple sclerosis (MS), degenerative cervical myelopathy (DCM), glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder. Notably, MN-166 has been evaluated in patients at risk of developing acute respiratory distress syndrome (ARDS).
As a clinical-stage biopharmaceutical firm, MediciNova focuses on developing a diverse portfolio of therapies for inflammatory, fibrotic, and neurodegenerative diseases. Its pipeline includes 11 clinical programs centered around MN-166 and MN-001 (tipelukast), which is currently undergoing a Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) following evaluations in idiopathic pulmonary fibrosis (IPF).
MediciNova continues to pursue government grants to fund its investigator-sponsored clinical trials, demonstrating a commitment to advancing its therapeutic offerings amidst a landscape filled with regulatory and financial challenges. The company emphasizes that any forward-looking statements made in this context involve inherent risks and uncertainties and may differ materially from actual results.
MWN-AI** Analysis
MediciNova, Inc. (NASDAQ: MNOV), with its focus on the treatment of neurodegenerative diseases, recently announced a significant step in advancing its lead candidate, MN-166 (ibudilast), in the Phase 2b/3 COMBAT-ALS clinical trial. The upcoming poster presentation at the 36th International Symposium on ALS/MND highlights the growing potential of MN-166 for treating Amyotrophic Lateral Sclerosis (ALS). As the trial progresses, this could be a pivotal moment, attracting attention from both investors and industry stakeholders.
The company's extensive pipeline—including candidates for progressive multiple sclerosis and Long COVID—underscores its commitment to addressing pressing health issues in the neurodegenerative space. MN-166’s ability to target inflammation through the inhibition of phosphodiesterase type-4 (PDE4) positions it uniquely within a competitive landscape of ALS treatments.
Investors should consider several strategic factors. First, the successful presentation and subsequent results from the COMBAT-ALS trial could catalyze stock price appreciation, especially if clinical outcomes are favorable. However, caution is warranted given the inherent risks in clinical trial progressions, especially in obtaining future funding and navigating FDA approval processes.
Moreover, MediciNova boasts a commendable history of securing grant-funded investigator-sponsored trials, indicating strong operational capabilities that could bode well for future fundraising efforts. Yet, the company remains reliant on partnerships and third-party cooperation for trial execution, which introduces uncertainties.
In summary, while MediciNova presents an alluring opportunity for investors looking at the biopharmaceutical sector, a balanced approach considering both upward potential and associated risks should guide decision-making, particularly as key trial milestones approach. Investors may want to stay abreast of developments and prepare for volatility that often accompanies clinical updates in biotech.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LA JOLLA, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the Phase 2b/3 COMBAT clinical trial of MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) patients has been selected for a poster presentation at 36 th International Symposium on ALS/MND to be held December 5-7, 2025 in San Diego, CA.
The presentation details are as follows:
Paper Number : 228
Title : COMBAT-ALS Phase 2b/3 Trial of MN-166 (Ibudilast) in ALS: Trial Update and Baseline Characteristics
Theme : Clinical Trial and Trial Design
About MN-166 (ibudilast)
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases such as ALS (amyotrophic lateral sclerosis), progressive MS (multiple sclerosis), and DCM (degenerative cervical myelopathy); and is also in development for glioblastoma, Long COVID, CIPN (chemotherapy-induced peripheral neuropathy), and substance use disorder. In addition, MN-166 (ibudilast) was evaluated in patients that are at risk for developing acute respiratory distress syndrome (ARDS).
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2024 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT :
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
FAQ**
What are the expected outcomes and implications of the COMBAT-ALS Phase 2b/3 trial results for MediciNova Inc. MNOV's future development strategies in ALS treatment?
How might MediciNova Inc. MNOV secure additional funding or partnerships to support the ongoing clinical trials for MN-166 (ibudilast) amidst the inherent risks associated with clinical development?
Can you elaborate on how the trial design in the COMBAT clinical trial aligns with both regulatory expectations and MediciNova Inc. MNOV's overall development pipeline strategy?
In terms of market potential, how does MediciNova Inc. MNOV plan to leverage the diverse applications of MN-166 (ibudilast) in treating various neurodegenerative diseases post-trial?
**MWN-AI FAQ is based on asking OpenAI questions about MediciNova Inc. (NASDAQ: MNOV).
NASDAQ: MNOV
MNOV Trading
1.45% G/L:
$1.40 Last:
8,403 Volume:
$1.41 Open:
